Alembic Pharma gets USFDA nod for eye infection treatment

Business Dec 11, 2025

Alembic Pharmaceuticals just scored final approval from the USFDA to launch its generic eye infection drops in the US.
The new treatment, available in one strength in two sizes, is set to enhance Alembic's presence in the American pharma scene.

What makes this approval special?

Alembic's drug is a generic version of Bausch & Lomb's Zylet and treats eye inflammation when there's also a risk of bacterial infection.
With its Competitive Generic Therapy (CGT) status, Alembic gets 180 days of exclusive sales once it hits the market—giving them a head start and giving patients more affordable options for treating eye issues.